BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32902906)

  • 21. Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes.
    Picou F; Vignon C; Debeissat C; Lachot S; Kosmider O; Gallay N; Foucault A; Estienne MH; Ravalet N; Bene MC; Domenech J; Gyan E; Fontenay M; Herault O
    Blood Adv; 2019 Dec; 3(24):4271-4279. PubMed ID: 31869414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of PPARδ in bone marrow endothelial progenitor cells improves their hematopoiesis-supporting ability after myelosuppressive injury.
    Liang M; Lyu ZS; Zhang YY; Tang SQ; Xing T; Chen YH; Wang Y; Jiang Q; Xu LP; Zhang XH; Huang XJ; Kong Y
    Cancer Lett; 2024 Jun; 592():216937. PubMed ID: 38704134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenic
    Osswald L; Hamarsheh S; Uhl FM; Andrieux G; Klein C; Dierks C; Duquesne S; Braun LM; Schmitt-Graeff A; Duyster J; Boerries M; Brummer T; Zeiser R
    Mol Cancer Res; 2021 Sep; 19(9):1596-1608. PubMed ID: 34088868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt's lymphoma.
    Granato M; Rizzello C; Romeo MA; Yadav S; Santarelli R; D'Orazi G; Faggioni A; Cirone M
    Int J Biochem Cell Biol; 2016 Oct; 79():393-400. PubMed ID: 27620077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pediatric MDS and bone marrow failure-associated germline mutations in SAMD9 and SAMD9L impair multiple pathways in primary hematopoietic cells.
    Thomas ME; Abdelhamed S; Hiltenbrand R; Schwartz JR; Sakurada SM; Walsh M; Song G; Ma J; Pruett-Miller SM; Klco JM
    Leukemia; 2021 Nov; 35(11):3232-3244. PubMed ID: 33731850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenotypic characterization of aberrant stem and progenitor cell populations in myelodysplastic syndromes.
    Ostendorf BN; Flenner E; Flörcken A; Westermann J
    PLoS One; 2018; 13(5):e0197823. PubMed ID: 29799854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow.
    Hofmann WK; de Vos S; Komor M; Hoelzer D; Wachsman W; Koeffler HP
    Blood; 2002 Nov; 100(10):3553-60. PubMed ID: 12411319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes.
    Falconi G; Fabiani E; Fianchi L; Criscuolo M; Raffaelli CS; Bellesi S; Hohaus S; Voso MT; D'Alò F; Leone G
    Exp Hematol; 2016 Jan; 44(1):75-83.e1-4. PubMed ID: 26521017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice.
    Chen TH; Kambal A; Krysiak K; Walshauser MA; Raju G; Tibbitts JF; Walter MJ
    Blood; 2011 Feb; 117(5):1530-9. PubMed ID: 21123823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes.
    Maratheftis CI; Andreakos E; Moutsopoulos HM; Voulgarelis M
    Clin Cancer Res; 2007 Feb; 13(4):1154-60. PubMed ID: 17317824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishment of a xenograft model of human myelodysplastic syndromes.
    Muguruma Y; Matsushita H; Yahata T; Yumino S; Tanaka Y; Miyachi H; Ogawa Y; Kawada H; Ito M; Ando K
    Haematologica; 2011 Apr; 96(4):543-51. PubMed ID: 21193418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice.
    Chai X; Li D; Cao X; Zhang Y; Mu J; Lu W; Xiao X; Li C; Meng J; Chen J; Li Q; Wang J; Meng A; Zhao M
    Sci Rep; 2015 May; 5():10181. PubMed ID: 25970748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes.
    Peng H; Wen J; Zhang L; Li H; Chang CC; Zu Y; Zhou X
    Mol Biosyst; 2012 Apr; 8(4):1366-74. PubMed ID: 22327869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS.
    Kornblau SM; Cohen AC; Soper D; Huang YW; Cesano A
    Cytometry B Clin Cytom; 2014 Nov; 86(6):383-96. PubMed ID: 24106013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression.
    Okamoto S; Tsujioka T; Suemori S; Kida J; Kondo T; Tohyama Y; Tohyama K
    Cancer Sci; 2016 Sep; 107(9):1302-14. PubMed ID: 27311589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution.
    Ainciburu M; Ezponda T; Berastegui N; Alfonso-Pierola A; Vilas-Zornoza A; San Martin-Uriz P; Alignani D; Lamo-Espinosa J; San-Julian M; Jiménez-Solas T; Lopez F; Muntion S; Sanchez-Guijo F; Molero A; Montoro J; Serrano G; Diaz-Mazkiaran A; Lasaga M; Gomez-Cabrero D; Diez-Campelo M; Valcarcel D; Hernaez M; Romero JP; Prosper F
    Elife; 2023 Jan; 12():. PubMed ID: 36629404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro biology of the hematopoietic system in myelodysplastic syndromes.
    Mayani H
    Cancer Treat Res; 2001; 108():25-43. PubMed ID: 11702602
    [No Abstract]   [Full Text] [Related]  

  • 39. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
    Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
    Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.
    Balderman SR; Li AJ; Hoffman CM; Frisch BJ; Goodman AN; LaMere MW; Georger MA; Evans AG; Liesveld JL; Becker MW; Calvi LM
    Blood; 2016 Feb; 127(5):616-25. PubMed ID: 26637787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.